Objectif Breast tumors are classified by several grading systems and divided into four main molecular subtypes: Luminal A, Luminal B, Triple negative/basal-like and HER2+. Since luminal A tumors tend to be ER+, their treatment often includes hormonal therapy. HER2+ tumors can be treated with Trastuzumab, an anti-Her2 receptor antibody. Hormonal therapies or Trastuzumab cannot be used for triple negative tumors, which are ER- and HER2-, and these are usually treated with a combination of surgery, radiotherapy and chemotherapy. There is an urgent need for new therapies to effectively treat different breast cancer subtypes. Translating basic knowledge on tumor cell biology into more effective diagnostic tools and improved treatments for patients remains difficult. The use of patient-derived xenografts (PDX) as preclinical models that recapitulate the complexity and heterogeneity of the human tumors should help to develop and successfully translate to the clinic new therapies. Our recent work provides genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to reduce breast tumor size and malignancy in vivo. Our results support a potential therapeutic use for p38 MAPK inhibitors in combination with chemotherapeutic drugs. The idea is to use PDX of specific breast cancer subtypes for preclinical validation of a new drug combination therapy with potential benefit to patients, which can be confirmed in clinical trials. Champ scientifique medical and health sciencesclinical medicinesurgerynatural sciencesbiological sciencescell biologymedical and health sciencesclinical medicineoncologybreast cancer Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-PoC-2015 - ERC Proof of Concept Grant Appel à propositions ERC-2015-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Contribution nette de l'UE € 149 995,00 Adresse CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA 08028 Barcelona Espagne Voir sur la carte Région Este Cataluña Barcelona Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 995,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Espagne Contribution nette de l'UE € 149 995,00 Adresse CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA 08028 Barcelona Voir sur la carte Région Este Cataluña Barcelona Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 995,00